Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 348,901 | 426,859 | 167,645 | 141,561 | -64,080 |
| Depreciation Amortization | 74,756 | 88,081 | 95,158 | 105,012 | 113,194 |
| Income taxes - deferred | 48,738 | 56,096 | -44,981 | -52,087 | -15,608 |
| Accounts receivable | -228,054 | -57,909 | -190,435 | -82,033 | 65,574 |
| Other Working Capital | -293,660 | -216,396 | -336,539 | -96,383 | 66,034 |
| Other Operating Activity | 877,313 | 276,110 | 468,411 | 159,832 | 139,422 |
| Operating Cash Flow | $827,994 | $572,841 | $159,259 | $175,902 | $304,536 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -18,074 | 222,768 | -3,633 | 8,186 | -246,094 |
| PPE Investments | -103,038 | -75,424 | -96,691 | -17,634 | -95,578 |
| Net Acquisitions | -285,193 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -7,937 | -11,994 | -10,920 | -10,581 | -23,647 |
| Other Investing Activity | -7,937 | -10,853 | -10,920 | -10,581 | -24,641 |
| Investing Cash Flow | $-414,242 | $136,491 | $-111,244 | $-20,029 | $-366,313 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | 0 | -494,987 | 0 | N/A | -3,039 |
| Common Stock Issued | 14,460 | 49,277 | 69,353 | 69,333 | 49,194 |
| Other Financing Activity | -56,854 | -80,737 | -88,080 | -87,983 | -46,203 |
| Financing Cash Flow | $-42,394 | $-526,447 | $-18,727 | $-18,650 | $-48 |
| Exchange Rate Effect | -2,521 | 4,830 | 1,308 | 32 | -57 |
| Beginning Cash Position | 942,842 | 755,127 | 724,531 | 587,276 | 649,158 |
| End Cash Position | 1,311,679 | 942,842 | 755,127 | 724,531 | 587,276 |
| Net Cash Flow | $368,837 | $187,715 | $30,596 | $137,255 | $-61,882 |
| Free Cash Flow | |||||
| Operating Cash Flow | 827,994 | 572,841 | 159,259 | 175,902 | 304,536 |
| Capital Expenditure | -103,038 | -85,424 | -96,691 | -120,959 | -95,578 |
| Free Cash Flow | 724,956 | 487,417 | 62,568 | 54,943 | 208,958 |